How to Get Tresiba in North Dakota

What Is Tresiba and Why Doctors Prescribe It

Insulin degludec is an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours, properties that distinguish it from glargine U-100 and detemir [1]. The FDA approved Tresiba in September 2015 for adults with type 1 and type 2 diabetes, and a pediatric indication for children aged 1 year and older followed [2]. Its flat pharmacokinetic profile allows flexible daily dosing windows of 8 to 40 hours between injections without meaningful loss of glycemic control, a property confirmed in the SWITCH 1 crossover trial [3].

The DEVOTE trial (N=7,637, NEJM 2017) compared degludec with glargine U-100 in adults with type 2 diabetes at high cardiovascular risk. Degludec was noninferior for major adverse cardiovascular events (hazard ratio 0.91 to 95% CI 0.78 to 1.06) and reduced the rate of severe hypoglycemia by 40% relative to glargine (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001) [4]. The American Diabetes Association (ADA) 2024 Standards of Care state: "Insulin degludec and glargine U-300 have lower rates of nocturnal hypoglycemia than glargine U-100, and either may be preferred when hypoglycemia is a concern" [5].

For patients in North Dakota, where rural geography can limit same-day clinic access, a once-daily basal insulin with a flexible injection window may reduce the burden of strict timing adherence.

[1] FDA labeling for degludec confirms the 25-hour half-life and 42-hour duration [2]. Prescribers include endocrinologists, family medicine physicians, internists, nurse practitioners (NPs), and physician assistants (PAs). All of these provider types hold prescriptive authority under North Dakota law [6].

Telehealth Prescribing of Tresiba in North Dakota

North Dakota permits telehealth prescribing of Tresiba. Providers licensed in North Dakota may issue prescriptions for Schedule-exempt medications, including all insulin products, via synchronous video or phone consultations [7]. Under the North Dakota Century Code Title 43, advanced practice registered nurses and PAs prescribe controlled and non-controlled medications within their scope, meaning you are not limited to physician-only telehealth platforms [6].

HealthRX connects patients to board-certified clinicians who can evaluate fasting glucose logs, HbA1c results, and prior basal insulin history during a single video visit. After the consultation, the prescription routes electronically to a pharmacy of your choice, including mail-order pharmacies that ship to North Dakota ZIP codes.

Steps to obtain Tresiba via telehealth in North Dakota:

1. Schedule a video visit and upload recent labs (HbA1c, fasting glucose, basic metabolic panel).
2. The clinician reviews your current regimen and documents medical necessity for degludec specifically.
3. An e-prescription is sent to your preferred pharmacy.
4. If your insurer requires prior authorization (PA), the clinician submits clinical notes and supporting documentation the same day.

A systematic review published in JAMA Internal Medicine (2023) found that telehealth diabetes management produced equivalent HbA1c reductions compared with in-person care (pooled mean difference -0.11%, 95% CI -0.25 to 0.03) across 22 randomized trials [8]. Rural states including North Dakota have disproportionately benefited from remote endocrinology access after CMS expanded telehealth coverage rules in 2020 [9].

What Labs Are Required Before Starting Tresiba

Before prescribing Tresiba, a North Dakota clinician will typically order a standard set of baseline labs. No lab test is unique to degludec compared with other basal insulins, but documentation of these values supports prior authorization approvals and sets a treatment baseline [10].

Required or strongly recommended labs before Tresiba initiation:

• HbA1c: Establishes current glycemic control. Most insurers require HbA1c >7.0% (or >8.0% for some PA criteria) to approve basal insulin [5].
• Fasting plasma glucose (FPG): Guides starting dose calculation. The FDA label recommends initiating degludec at 10 units once daily in insulin-naive type 2 patients and titrating by 2 units every 3 days to a fasting target of 80 to 90 mg/dL [2].
• Basic metabolic panel (BMP): Checks renal function. Moderate to severe renal impairment increases hypoglycemia risk with any insulin and may require dose reduction [2].
• C-peptide and fasting insulin (type 1 workup): Confirms residual beta-cell function when the diagnosis is uncertain.
• Thyroid-stimulating hormone (TSH): Hypothyroidism alters insulin sensitivity and is prevalent in patients with type 1 diabetes [11].
• Lipid panel: Requested by most endocrinologists as part of comprehensive diabetes management per ADA standards [5].

The ADA 2024 Standards of Care specify: "At least twice-yearly HbA1c testing is recommended for patients who are meeting treatment goals; quarterly testing is appropriate when therapy has changed or when goals are not being met" [5]. Having a recent HbA1c (within 90 days) in hand before your telehealth visit avoids delays in prior authorization submission.

Prior Authorization for Tresiba in North Dakota

Prior authorization is required by most commercial insurers operating in North Dakota. Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medica, the three largest individual-market carriers in the state, each list insulin degludec under a non-preferred tier requiring PA documentation [12].

Typical PA criteria for Tresiba in North Dakota include:

• Diagnosis of type 1 or type 2 diabetes with ICD-10 code E10.x or E11.x
• HbA1c above plan threshold (commonly >7.5% or >8.0%)
• Trial and failure of, or contraindication to, at least one preferred basal insulin (usually glargine U-100 or biosimilar)
• Clinical rationale for degludec (hypoglycemia risk, injection flexibility, patient-specific factor)

The "step therapy" requirement, often called fail-first, means your prescriber must document that glargine U-100 (e.g., Lantus, Basaglar) caused inadequate control or clinically significant hypoglycemia before the plan approves degludec. The DEVOTE trial data showing a 40% reduction in severe hypoglycemic events [4] is the primary clinical evidence your prescriber will cite to satisfy this criterion.

PA decisions in North Dakota typically take 3 to 5 business days. Urgent requests filed with supporting lab documentation may be processed within 24 to 72 hours under state urgent-care rules [13]. If the PA is denied, your clinician can file a peer-to-peer review appeal within 30 days.

North Dakota Medicaid does not cover Tresiba as of 2025. Medicaid enrollees should discuss coverage for glargine-based alternatives or apply for the Novo Nordisk Patient Assistance Program (PAP), which provides Tresiba at no cost to qualifying uninsured or underinsured patients with household income at or below 400% of the federal poverty level [14].

How Long Until You Receive Tresiba in North Dakota

Timing depends on the prescribing pathway and insurance status.

Cash-pay or pre-authorized patients: A telehealth visit can be completed the same day you book. The e-prescription reaches the pharmacy within minutes of the visit ending. Most retail pharmacies in Fargo, Bismarck, Grand Forks, and Minot stock Tresiba FlexTouch pens in both U-100 and U-200 strengths. Same-day pickup is common at larger chains [15]. Rural North Dakota pharmacies (serving towns <5,000 residents) may require a 24 to 48-hour order.

Insurance with prior authorization: Add 3 to 7 business days for PA processing. Telehealth platforms that include PA services can submit documentation immediately after the visit, shaving 1 to 2 days off the typical timeline.

Mail-order pharmacies: Shipping to North Dakota ZIP codes generally takes 2 to 5 business days. Some mail-order services offer overnight shipping at additional cost. Many insurance plans require mail-order for 90-day supplies once the drug is authorized.

The HealthRX clinical team developed the following decision framework for estimating time-to-medication for North Dakota Tresiba patients:

| Scenario | Estimated Days to First Dose | |---|---| | Cash pay, retail pharmacy (urban ND) | 0 to 1 | | Cash pay, rural ND pharmacy | 1 to 3 | | Insurance, PA required, PA approved | 4 to 9 | | Insurance, PA denied, appeal successful | 14 to 30 | | Mail-order, 90-day supply | 3 to 7 |

Transferring an Existing Tresiba Prescription to North Dakota

Patients relocating to North Dakota or establishing care after moving can transfer an active Tresiba prescription from an out-of-state pharmacy. North Dakota law allows pharmacist-to-pharmacist transfers of non-controlled prescriptions, and insulin is not a controlled substance at the federal or state level [16].

To transfer a Tresiba prescription:

1. Contact your new North Dakota pharmacy and provide the name and phone number of your previous pharmacy.
2. The receiving pharmacist contacts the dispensing pharmacist to verify the prescription and remaining refills.
3. The prescription is re-created at the new pharmacy, retaining original prescriber information.

If the original prescription has no refills remaining, your new North Dakota provider, including a telehealth clinician, can issue a new prescription after a chart review or initial visit. Bring the original prescription label, your most recent lab results, and a list of current medications to expedite the consultation.

Transferring across state lines is legally straightforward for insulin. The DEA schedule status does not apply to insulin products [16]. One practical limit: if your previous state used a paper prescription (some states still require them for certain drugs), your new North Dakota pharmacy cannot accept a photocopy and you will need a new prescription from a licensed ND provider [17].

Tresiba Dosing Basics Every North Dakota Patient Should Know

The FDA-approved starting dose for insulin-naive adults with type 2 diabetes is 10 units subcutaneously once daily [2]. For patients transitioning from another basal insulin, the dose conversion is unit-to-unit: if you were taking 30 units of glargine U-100 once daily, you start 30 units of degludec once daily, then titrate [2].

The recommended titration algorithm from the FDA label is:

• Adjust by 2 units every 3 days.
• Target fasting self-monitored blood glucose of 80 to 90 mg/dL.
• Do not adjust based on a single fasting reading; use the mean of three consecutive fasting values [2].

The SWITCH 2 trial (N=721, type 2 diabetes) demonstrated that patients switching from glargine U-100 to degludec achieved a significantly lower rate of confirmed hypoglycemic episodes (rate ratio 0.70 to 95% CI 0.61 to 0.81) with equivalent HbA1c reduction after 32 weeks [18]. These data directly support the PA documentation language your clinician will use.

Tresiba U-200 FlexTouch delivers 200 units/mL, making it the highest-concentration basal insulin available in the United States. Patients requiring more than 40 units per day may prefer U-200 to reduce injection volume. Dose selection between U-100 and U-200 is based on clinical need, not insurance tier, though some plans restrict coverage to one formulation [2].

Inject into the abdomen, thigh, or upper arm. Rotate sites within the same region. Never inject into a lipohypertrophic area, as absorption becomes erratic and unpredictable [19]. The pen should reach room temperature before injection to reduce discomfort; do not freeze Tresiba or expose it to direct sunlight [2].

503A Pharmacy Access for Insulin Degludec in North Dakota

North Dakota has licensed 503A compounding pharmacies that operate under state Board of Pharmacy oversight [20]. A 503A pharmacy may prepare patient-specific compounded formulations of insulin degludec with a valid prescription from a licensed prescriber. However, the FDA has not approved any compounded insulin degludec product, and the agency has issued guidance clarifying that compounded drug products are not FDA-approved and lack the safety, efficacy, and manufacturing quality data of the commercially approved Tresiba [21].

Compounding is typically pursued when a patient has a documented allergy to an excipient in the commercial formulation, requires a concentration not available commercially, or cannot access the brand product due to cost. Given the availability of Novo Nordisk PAP and the Tresiba Savings Card (which reduces out-of-pocket cost to as low as $99 per month for eligible commercially insured patients) [14], most patients do not need a compounded alternative.

If you are considering a compounded degludec product, confirm that the compounding pharmacy holds an active North Dakota license, verify that the prescriber has documented a specific clinical rationale for compounding, and discuss the absence of FDA approval data with your clinician [20] [21].

Cost and Savings Programs for Tresiba in North Dakota

The list price of Tresiba FlexTouch (5 pens, 3 mL each) is approximately $530 to $560 per package in 2025. Out-of-pocket cost varies widely by plan design.

Options to reduce cost in North Dakota:

Novo Nordisk Tresiba Savings Card: Commercially insured patients (not Medicaid or Medicare Part D) may pay as low as $99 per fill. The program is available through the Novo Nordisk website and can be activated before the first prescription is filled [14].

Novo Nordisk Patient Assistance Program: Uninsured or underinsured patients meeting income criteria receive Tresiba at no cost. Applications are available online and require proof of income and a signed prescriber form [14].

GoodRx and cash-pay pharmacies: GoodRx pricing for Tresiba U-100 (5 pens) in North Dakota cities ranges from approximately $380 to $480 with discount coupons, which may undercut the cost after a non-preferred copay for some insurance plans [15].

Medicare Part D: Tresiba's tier placement varies by plan formulary. The Inflation Reduction Act (IRA) capped Medicare Part D insulin cost-sharing at $35 per month beginning January 2023 [22]. Patients on Medicare Part D pay no more than $35 per month for any covered insulin, including degludec if it appears on their plan formulary. Review your plan's formulary at open enrollment to confirm degludec is listed.

The ADA's 2024 Standards of Care note: "Cost is a barrier to insulin access for many patients; clinicians should be familiar with patient assistance programs and formulary options" [5]. If cost remains prohibitive after exhausting manufacturer programs, glargine U-300 (Toujeo) or biosimilar glargine products represent clinically similar alternatives with potentially lower net cost on some ND formularies.

Who Can Prescribe Tresiba in North Dakota

Under North Dakota law, the following providers hold independent prescriptive authority for non-controlled medications including insulin degludec [6]:

• Licensed physicians (MD, DO)
• Advanced Practice Registered Nurses (APRN) with prescriptive authority, including certified nurse practitioners (CNP) and certified clinical nurse specialists (CCNS)
• Physician Assistants (PA) under North Dakota PA Practice Act

APRNs in North Dakota practice under a collaborative practice agreement with a physician for certain clinical scenarios, but prescriptive authority for non-controlled drugs does not require a physician co-signature on the prescription itself [6]. This means a telehealth NP or PA on the HealthRX platform can issue a valid, standalone Tresiba prescription to a North Dakota patient.

Pharmacists in North Dakota do not hold independent prescriptive authority for insulin under current state law, though they can dispense under a valid prescription and provide clinical consultation [17].